Cargando…

A retrospective study of late adverse events in proton beam therapy for prostate cancer

The efficacy and safety of proton beam therapy (PBT) were retrospectively evaluated in 111 consecutive patients with prostate cancer who underwent definitive PBT between 2008 and 2012. Following exclusion of 18 patients due to treatment suspension, loss to follow-up, and histology, the analysis incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Makishima, Hirokazu, Ishikawa, Hitoshi, Tanaka, Keiichi, Mori, Yutaro, Mizumoto, Masashi, Ohnishi, Kayoko, Aihara, Teruhito, Fukumitsu, Nobuyoshi, Okumura, Toshiyuki, Sakurai, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5639311/
https://www.ncbi.nlm.nih.gov/pubmed/29046789
http://dx.doi.org/10.3892/mco.2017.1372
_version_ 1783270858958045184
author Makishima, Hirokazu
Ishikawa, Hitoshi
Tanaka, Keiichi
Mori, Yutaro
Mizumoto, Masashi
Ohnishi, Kayoko
Aihara, Teruhito
Fukumitsu, Nobuyoshi
Okumura, Toshiyuki
Sakurai, Hideyuki
author_facet Makishima, Hirokazu
Ishikawa, Hitoshi
Tanaka, Keiichi
Mori, Yutaro
Mizumoto, Masashi
Ohnishi, Kayoko
Aihara, Teruhito
Fukumitsu, Nobuyoshi
Okumura, Toshiyuki
Sakurai, Hideyuki
author_sort Makishima, Hirokazu
collection PubMed
description The efficacy and safety of proton beam therapy (PBT) were retrospectively evaluated in 111 consecutive patients with prostate cancer who underwent definitive PBT between 2008 and 2012. Following exclusion of 18 patients due to treatment suspension, loss to follow-up, and histology, the analysis included 93 patients with a median age of 68 years (range, 49–81 years). A total of 7, 32 and 54 prostate cancer patients were classified as low-, intermediate- and high-risk, respectively, as follows: High-risk, T≥3a or prostate-specific antigen (PSA) ≥20 ng/ml or Gleason Score ≥8; low-risk, T ≤2b and PSA≤10 ng/ml and Gleason Score=6; intermediate-risk, all other combinations. The median initial prostate-specific antigen (PSA) level was 9.75 ng/ml (range, 1.4–100 ng/ml) and the median Gleason score was 7 (range, 6–10). Patients with low-risk disease received 74 GyE (relative biological effectiveness=1.1) in 37 fractions, and those at intermediate or higher risk received 78 GyE in 39 fractions. Complete androgen blockade (CAB) therapy was performed from 6 months prior to PBT for patients with intermediate- or high-risk disease. CAB was continued during PBT and then terminated at the end of PBT for intermediate-risk patients. Patients at high risk continued CAB for 3 years. No combination therapy was used for low-risk patients. All the patients were followed up for >2 years after PBT, and all but one were PSA failure-free. The Common Terminology Criteria for Adverse Events v.4.0 was used to evaluate late adverse events. One patient developed grade 3 non-infectious cystitis and hematuria. Grade 2 urinary frequency was observed in 1 patient, and grade 2 rectal bleeding occurred in 4 patients. Of the 4 patients with grade 2 rectal bleeding, 2 received anticoagulant therapy, but none had diabetes mellitus or another high-risk comorbidity. The median time to occurrence of an adverse event of grade ≥2 was 14 months (range, 3–41 months). Therefore, the present retrospective study revealed that PBT at 78 GyE/39 Fr was well-tolerated and achieved good tumor control in patients with prostate cancer.
format Online
Article
Text
id pubmed-5639311
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-56393112017-10-18 A retrospective study of late adverse events in proton beam therapy for prostate cancer Makishima, Hirokazu Ishikawa, Hitoshi Tanaka, Keiichi Mori, Yutaro Mizumoto, Masashi Ohnishi, Kayoko Aihara, Teruhito Fukumitsu, Nobuyoshi Okumura, Toshiyuki Sakurai, Hideyuki Mol Clin Oncol Articles The efficacy and safety of proton beam therapy (PBT) were retrospectively evaluated in 111 consecutive patients with prostate cancer who underwent definitive PBT between 2008 and 2012. Following exclusion of 18 patients due to treatment suspension, loss to follow-up, and histology, the analysis included 93 patients with a median age of 68 years (range, 49–81 years). A total of 7, 32 and 54 prostate cancer patients were classified as low-, intermediate- and high-risk, respectively, as follows: High-risk, T≥3a or prostate-specific antigen (PSA) ≥20 ng/ml or Gleason Score ≥8; low-risk, T ≤2b and PSA≤10 ng/ml and Gleason Score=6; intermediate-risk, all other combinations. The median initial prostate-specific antigen (PSA) level was 9.75 ng/ml (range, 1.4–100 ng/ml) and the median Gleason score was 7 (range, 6–10). Patients with low-risk disease received 74 GyE (relative biological effectiveness=1.1) in 37 fractions, and those at intermediate or higher risk received 78 GyE in 39 fractions. Complete androgen blockade (CAB) therapy was performed from 6 months prior to PBT for patients with intermediate- or high-risk disease. CAB was continued during PBT and then terminated at the end of PBT for intermediate-risk patients. Patients at high risk continued CAB for 3 years. No combination therapy was used for low-risk patients. All the patients were followed up for >2 years after PBT, and all but one were PSA failure-free. The Common Terminology Criteria for Adverse Events v.4.0 was used to evaluate late adverse events. One patient developed grade 3 non-infectious cystitis and hematuria. Grade 2 urinary frequency was observed in 1 patient, and grade 2 rectal bleeding occurred in 4 patients. Of the 4 patients with grade 2 rectal bleeding, 2 received anticoagulant therapy, but none had diabetes mellitus or another high-risk comorbidity. The median time to occurrence of an adverse event of grade ≥2 was 14 months (range, 3–41 months). Therefore, the present retrospective study revealed that PBT at 78 GyE/39 Fr was well-tolerated and achieved good tumor control in patients with prostate cancer. D.A. Spandidos 2017-10 2017-08-11 /pmc/articles/PMC5639311/ /pubmed/29046789 http://dx.doi.org/10.3892/mco.2017.1372 Text en Copyright: © Makishima et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Makishima, Hirokazu
Ishikawa, Hitoshi
Tanaka, Keiichi
Mori, Yutaro
Mizumoto, Masashi
Ohnishi, Kayoko
Aihara, Teruhito
Fukumitsu, Nobuyoshi
Okumura, Toshiyuki
Sakurai, Hideyuki
A retrospective study of late adverse events in proton beam therapy for prostate cancer
title A retrospective study of late adverse events in proton beam therapy for prostate cancer
title_full A retrospective study of late adverse events in proton beam therapy for prostate cancer
title_fullStr A retrospective study of late adverse events in proton beam therapy for prostate cancer
title_full_unstemmed A retrospective study of late adverse events in proton beam therapy for prostate cancer
title_short A retrospective study of late adverse events in proton beam therapy for prostate cancer
title_sort retrospective study of late adverse events in proton beam therapy for prostate cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5639311/
https://www.ncbi.nlm.nih.gov/pubmed/29046789
http://dx.doi.org/10.3892/mco.2017.1372
work_keys_str_mv AT makishimahirokazu aretrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT ishikawahitoshi aretrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT tanakakeiichi aretrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT moriyutaro aretrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT mizumotomasashi aretrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT ohnishikayoko aretrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT aiharateruhito aretrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT fukumitsunobuyoshi aretrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT okumuratoshiyuki aretrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT sakuraihideyuki aretrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT makishimahirokazu retrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT ishikawahitoshi retrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT tanakakeiichi retrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT moriyutaro retrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT mizumotomasashi retrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT ohnishikayoko retrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT aiharateruhito retrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT fukumitsunobuyoshi retrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT okumuratoshiyuki retrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer
AT sakuraihideyuki retrospectivestudyoflateadverseeventsinprotonbeamtherapyforprostatecancer